Jake Shortt
YOU?
Author Swipe
View article: Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE)
Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE) Open
Despite achieving remission, patients with AML have a substantial risk of relapse, particularly if adverse molecular risk, elderly or if measurable residual disease (MRD) is present after therapy. A phase 3 study has demonstrated that main…
View article: P300/CBP acetyltransferase inhibition and degradation disrupt oncogenic transcriptional programs and reveal epigenetic vulnerabilities in multiple myeloma
P300/CBP acetyltransferase inhibition and degradation disrupt oncogenic transcriptional programs and reveal epigenetic vulnerabilities in multiple myeloma Open
Background: The histone acetyltransferases (HATs) P300 and CBP are critical transcriptional co-activators that regulate gene expression by catalyzing lysine acetylation on histones and non-histone substrates. These co-activators are essent…
View article: An immunometabolic companion biomarker to enhance FDG-PET interpretation and guide frontline therapy in follicular lymphoma
An immunometabolic companion biomarker to enhance FDG-PET interpretation and guide frontline therapy in follicular lymphoma Open
Introduction: Bendamustine-based immunochemotherapy (ICT) is a standard frontline regimen for follicular lymphoma (FL) but has limited efficacy in high-grade lymphomas characterised by rapid B cell proliferation. In clinical practice, Stan…
View article: Red blood cell transfusion practice and cardiac comorbidities in patients with myelodysplastic syndromes
Red blood cell transfusion practice and cardiac comorbidities in patients with myelodysplastic syndromes Open
Background Evidence guiding optimal transfusion practice for patients with myelodysplastic syndromes (MDS) is lacking. Many patients have concurrent cardiac disease. Data on practice are sparse. We aimed to describe the use of red blood ce…
View article: Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury
Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury Open
View article: Dynamic Profiling of Cell Free Tumour DNA in Aggressive B‐Cell Lymphoma From Diagnosis to Transformation at Relapse
Dynamic Profiling of Cell Free Tumour DNA in Aggressive B‐Cell Lymphoma From Diagnosis to Transformation at Relapse Open
Background Next generation sequencing (NGS) of cell free tumour DNA (ctDNA) provides a snapshot of lymphoma mutations correlating with tumour burden. We evaluated the ability of ctDNA to molecularly profile and track disease burden in pati…
View article: T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial
T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial Open
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are highly radiosensitive with immune-driven abscopal responses reported. Programmed cell death 1/programmed cell death ligand 1 (PD-L1) inhibitors are relatively ineffecti…
View article: Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS Trial Open
View article: Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus
Targeted protein degraders of SARS-CoV-2 Mpro are more active than enzymatic inhibition alone with activity against nirmatrelvir resistant virus Open
This work demonstrates the feasibility of generating degraders from viral protein inhibitors, and confirms that degraders possess higher antiviral potency and activity against resistant virus, compared to size matched non-degrading enzymat…
View article: Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice
Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice Open
View article: Aligning kidney function assessment in patients with cancer to global practices in internal medicine
Aligning kidney function assessment in patients with cancer to global practices in internal medicine Open
View article: Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach
Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach Open
Background After pharmaceutical benefits scheme approval of midostaurin for fms‐like tyrosine kinase 3 ( FLT3 )‐mutated acute myeloid leukaemia (AML) in 2018, the Australasian Leukaemia & Lymphoma Group (ALLG) proposed a consensus approach…
View article: Data from A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas
Data from A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas Open
Purpose:Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimt…
View article: Supplementary Data 1 from A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas
Supplementary Data 1 from A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas Open
Supplementary methods including full inclusion/exclusion criteria, Supplementary Tables 1–5 (includes study representativeness table), and Supplementary Figure 1
View article: VHL-independent degradation of hepatitis B virus e antigen (HBeAg) by VHL-binding chimeric small molecules
VHL-independent degradation of hepatitis B virus e antigen (HBeAg) by VHL-binding chimeric small molecules Open
Chimeric small molecule LH-3, designed to recruit the VHL E3 ligase, degrades HBV protein HBeAg through a largely VHL-independent mechanism. Virological assessment reveals enhanced efficacy against an inhibitor-resistant strain of the viru…
View article: Principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision
Principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision Open
Single-nucleotide variants (SNVs) are extremely prevalent in human cancers, although most of these remain clinically unactionable. The programmable RNA nuclease CRISPR-Cas13 has been deployed to specifically target oncogenic RNAs. However,…
View article: Targeted protein degraders of SARS-CoV-2 Mpro demonstrate superior antiviral activity over enzymatic inhibition alone and potency against nirmatrelvir resistant virus
Targeted protein degraders of SARS-CoV-2 Mpro demonstrate superior antiviral activity over enzymatic inhibition alone and potency against nirmatrelvir resistant virus Open
Targeted viral protein degraders, which enable physical elimination of viral protein target to inhibit all its primary and ancillary functions, could provide a new avenue to more effective antiviral drugs, overcoming the limitations associ…
View article: A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas
A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas Open
Purpose: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acim…
View article: Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy Open
View article: Mapping the <scp>IM</scp> i <scp>D</scp> ‐dependent cereblon interactome using <scp>B</scp> io <scp>ID</scp> ‐proximity labelling
Mapping the <span>IM</span> i <span>D</span> ‐dependent cereblon interactome using <span>B</span> io <span>ID</span> ‐proximity labelling Open
Immunomodulatory imide drugs (IMiDs) are central components of therapy for multiple myeloma (MM). IMiDs bind cereblon (CRBN), an adaptor for the CUL4‐DDB1‐RBX1 E3 ligase to change its substrate specificity and induce degradation of ‘neosub…
View article: Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy
Intravitreal anti-vascular endothelial growth factor therapy in the treatment of vision loss associated with hematologic malignancy Open
View article: Sequential high‐dose methotrexate and cytarabine administration improves outcomes in real‐world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance
Sequential high‐dose methotrexate and cytarabine administration improves outcomes in real‐world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance Open
Background Despite recent advances, optimal therapeutic approaches applicable to subpopulations with primary central nervous system (CNS) lymphoma outside of clinical trials remain to be determined. Methods We performed a retrospective stu…
View article: Large cell lymphoma through a liquid lens
Large cell lymphoma through a liquid lens Open
Liquid biopsy to provide a mutational snapshot of diffuse large B‐cell lymphoma is an emerging technology of exciting potential utility. The report by Alcoceba et al. assesses the tractability of the EuroClonality‐NDC assay to profile lymp…
View article: An association between Dasatinib, elevated left atrial pressure and pleural effusion
An association between Dasatinib, elevated left atrial pressure and pleural effusion Open
Among patients with CML, there was an association between Dasatinib use, PE and elevated LAP on TTE. These findings are hypothesis generating and further studies are required to evaluate the utility of elevated LAP on TTE as a novel marker…
View article: How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?
How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials? Open
View article: Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n‐of‐1 trial of weekly‐interval red cell transfusion in myelodysplastic syndromes
Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n‐of‐1 trial of weekly‐interval red cell transfusion in myelodysplastic syndromes Open
Background Anemia in myelodysplastic syndromes (MDS) is associated with poorer health‐related quality of life (HRQoL) and physical function, and is frequently treated with transfusions. The current common practice of transfusing multiple r…
View article: EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL
EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS EPOETIN ALFA IN ERYTHROPOIESIS-STIMULATING AGENT (ESA)-NAIVE PATIENTS WITH TRANSFUSION-DEPENDENT LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS): FULL ANALYSIS OF THE COMMANDS TRIAL Open
Introduction: We report the full analysis of the COMMANDS trial assessing efficacy and safety of luspatercept versus epoetin alfa (EA) in ESA-naive patients with LR-MDS. Methods: 363 patients (aged ≥18 y, with transfusion-dependent LR-MDS,…
View article: The Nature of High-Risk Defining Events in Follicular Lymphoma Determines Overall Survival
The Nature of High-Risk Defining Events in Follicular Lymphoma Determines Overall Survival Open
Background: A subset of follicular lymphoma (FL) patients will experience a ‘high-risk defining event’ (HRDE) that portends poor survival due to early progression of disease or transformation to diffuse large B cell lymphoma (TFL). Progres…
View article: Molecular principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision
Molecular principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision Open
Single nucleotide variants (SNVs) are extremely prevalent in human cancers. For instance, KRAS mutations occur in over 90% of pancreatic cancers and ∼40% of colorectal cancers. Virtually all KRAS mutations are SNVs, most of which remain cl…
View article: MDS-234 Reduction of Transfusion Burden (TB), Hemoglobin Increase, and Dose Titration in the COMMANDS Study of Luspatercept Versus Epoetin Alfa (EA) in Erythropoietin-Stimulating Agent (ESA)-Naive Patients With Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)
MDS-234 Reduction of Transfusion Burden (TB), Hemoglobin Increase, and Dose Titration in the COMMANDS Study of Luspatercept Versus Epoetin Alfa (EA) in Erythropoietin-Stimulating Agent (ESA)-Naive Patients With Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Open